VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

The Role of Biomarkers in Neuroendocrine Tumors

Panelists: Matthew H. Kulke, MD, Dana-Farber; Pamela L. Kunz, MD, Stanford; Rodney F. Pommier, MD, OHSU; James C. Yao, MD, MD Anderson
Published: Thursday, Mar 21, 2013
For High-Definition, Click
Biomarkers can be used in a variety of ways for the management of patients with neuroendocrine tumors (NETs). James C. Yao, MD, notes that biomarkers may be used to aid in screening, diagnosis, prognosis, and predictively to select optimal treatments.

Varying levels of evidence and recommendations exist concerning biomarkers in NETs. Unfortunately, due to the intrinsic nature of the disease, a successful biomarker does not exist for screening patients, Yao regrets. However, to help diagnosis carcinoid tumors, Yao recommends the 5-HIAA test, which measures average serotonin levels over a 24 hour period. This marker is helpful but is not sufficient by itself to make a diagnosis.

Overall, selecting the most appropriate test should be tailored to the individual patient’s needs based on their symptoms. Yao and Rodney F. Pommier, MD, both agree that the markers examined should be selected very specifically on a patient-to-patient basis.
Slider Left
Slider Right
For High-Definition, Click
Biomarkers can be used in a variety of ways for the management of patients with neuroendocrine tumors (NETs). James C. Yao, MD, notes that biomarkers may be used to aid in screening, diagnosis, prognosis, and predictively to select optimal treatments.

Varying levels of evidence and recommendations exist concerning biomarkers in NETs. Unfortunately, due to the intrinsic nature of the disease, a successful biomarker does not exist for screening patients, Yao regrets. However, to help diagnosis carcinoid tumors, Yao recommends the 5-HIAA test, which measures average serotonin levels over a 24 hour period. This marker is helpful but is not sufficient by itself to make a diagnosis.

Overall, selecting the most appropriate test should be tailored to the individual patient’s needs based on their symptoms. Yao and Rodney F. Pommier, MD, both agree that the markers examined should be selected very specifically on a patient-to-patient basis.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x